ZETA-1 Phase 2 Trial Safety and Tolerability Results for of APX3330: A Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
APX3330
Presented at Women in Ophthalmology 2023
Filter by:
ZETA-1 Phase 2 Trial Efficacy Results for APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
APX3330
Presented at American Society of Retina Specialists 2023
ZETA-1 Phase 2 Trial Safety and Tolerability results for APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
APX3330
Presented at American Society of Retina Specialists 2023
Early Intervention for Diabetic Retinopathy (DR); Safety and Efficacy of novel, oral therapeutic APX3330 from ZETA-1 Phase 2 Trial
APX3330
Presented at American Society of Cataract and Refractive Surgery 2023
LYNX-1: A Pivotal Phase 3 Double-Masked, Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbance
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2023
LYNX-1 Phase 3 Trial: Phentolamine Ophthalmic Solution Improves Photic Symptoms and Quality of Life in Night Vision Disturbance Patients
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2023
Phentolamine Ophthalmic Solution Utilizes a Novel Alpha-1 Antagonist Mechanism for Improving Near Visual Acuity in the VEGA-1 Phase 2 Trial
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2023
Effect of Phentolamine Ophthalmic Solution on Accommodation, Visual Acuity, and Restoration of Pupillary Light Reflex in the MIRA-3 study Paper ID 92001
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2023
LYNX-1 Phase 3 trial: Phentolamine Ophthalmic Solution (POS) Proves Effective in Post-Lasik Patients with Dim Light Vision Disturbances
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2023
